WO2021136523A1 - 一种用于治疗肿瘤的药物组合及其应用 - Google Patents
一种用于治疗肿瘤的药物组合及其应用 Download PDFInfo
- Publication number
- WO2021136523A1 WO2021136523A1 PCT/CN2020/142257 CN2020142257W WO2021136523A1 WO 2021136523 A1 WO2021136523 A1 WO 2021136523A1 CN 2020142257 W CN2020142257 W CN 2020142257W WO 2021136523 A1 WO2021136523 A1 WO 2021136523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 150000003839 salts Chemical class 0.000 claims abstract description 98
- 239000012453 solvate Substances 0.000 claims abstract description 88
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 239000012270 PD-1 inhibitor Substances 0.000 claims abstract description 49
- 239000012668 PD-1-inhibitor Substances 0.000 claims abstract description 49
- 229940121655 pd-1 inhibitor Drugs 0.000 claims abstract description 49
- 239000012271 PD-L1 inhibitor Substances 0.000 claims abstract description 48
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 239000007924 injection Substances 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 28
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 15
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 206010038389 Renal cancer Diseases 0.000 claims description 14
- 201000010982 kidney cancer Diseases 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 239000000890 drug combination Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 206010005949 Bone cancer Diseases 0.000 claims description 7
- 208000018084 Bone neoplasm Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 9
- 230000006838 adverse reaction Effects 0.000 abstract description 9
- 230000004614 tumor growth Effects 0.000 abstract description 8
- 230000001154 acute effect Effects 0.000 abstract description 4
- 238000002648 combination therapy Methods 0.000 abstract description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 44
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 18
- 239000012661 PARP inhibitor Substances 0.000 description 13
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 13
- 238000010171 animal model Methods 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229950009791 durvalumab Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 8
- 239000003446 ligand Substances 0.000 description 7
- 229960000572 olaparib Drugs 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 229950002916 avelumab Drugs 0.000 description 4
- 201000000053 blastoma Diseases 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000008184 embryoma Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000002518 glial effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 230000033590 base-excision repair Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 229940066453 tecentriq Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091007743 BRCA1/2 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Definitions
- the invention relates to a drug combination for treating tumors and its application.
- PARP Polyadenosine diphosphate ribose polymerase
- BER DNA base excision repair
- HRD homologous recombination with DNA repair pathway Defects
- the PARP inhibitor olaparib was approved for the treatment of advanced ovarian cancer in the EU and the United States at the same time, marking the first clinical establishment of the feasibility of PARP inhibitors as anti-tumor targets and co-lethal theory.
- PARP inhibitors there are 4 PARP inhibitors on the market worldwide, and olaparib entered the Chinese market in 2018.
- Mefuperil hydrochloride disclosed in patent WO2013117120 (its structural formula is ), the structure is novel, and its nucleus 2-arylfuran is widely present in active natural products, and it is also one of the dominant structures in medicinal chemistry, and has a good prospect of being a medicine.
- the PARP inhibitor has good water solubility (>35mg/ml, more than 350 times higher than olaparib), simple synthesis process, simple preparation, good stability, excellent pharmacokinetic properties, high tissue distribution, and easy penetration of blood brain Barriers and other advantages. These characteristics provide an important basis for the treatment of a variety of malignant tumors with mefuroperil hydrochloride.
- Tumor immunotherapy is to mobilize the body's immune system to enhance anti-tumor immunity, thereby inhibiting and killing tumor cells.
- Tumor immunotherapy is one of the most promising research directions in the current tumor treatment field.
- PD-1 programmed death-1
- PD-1 receptor for programmed death Because it is related to apoptosis, it is named as the PD-1 receptor for programmed death, and the PD-1 receptor for programmed death It is an important immunosuppressive molecule and a member of the CD28 superfamily.
- PD-1 is mainly expressed in activated T cells and B cells, and is a surface receptor of activated T cells.
- PD-1 has two ligands, namely PD-L1 (B7-H1) and PD-L2 (B7-DC).
- the tumor microenvironment in the body will induce the infiltrating T cells to highly express PD-1 molecules, and the tumor cells will highly express PD-1 ligands PD-L1 and PD-L2, leading to continuous activation of the PD-1 pathway in the tumor microenvironment.
- PD-L1 After PD-L1 is connected to PD-1, the function of T cells is inhibited and cannot send a signal to the immune system to attack the tumor.
- PD-1 inhibitors including PD-1 antibody and PD-L1 antibody, are a new tumor immunotherapy drug. Unlike surgery, radiotherapy and chemotherapy, and targeted drugs, PD-1 inhibitors themselves cannot directly kill cancer cells, but fight cancer by activating the patient's own immune system.
- PD-1 inhibitors have been marketed in dozens of countries including China, the United States and Europe, including 2 PD-1 antibodies and 3 PD-L1 antibodies, namely Opdivo (Nivolumab), Keytruda (Pembrolizumab), Tecentriq (Atezolizumab), Imfinzi (Durvalumab), Bavencio (Avelumab), of which Opdivo and Keytruda have been listed in China.
- 3 types of PD-1 from domestic pharmaceutical companies have also been listed, namely Junshi’s Teriplimumab (Tuoyi), Cinda’s Sintilizumab (Daboshu) and Hengrui’s Card. Relizumab (erika).
- the MEDIOLA Phase II trial is a PD-L1 antibody Imfinzi (Durvalumab) combined with a PARP inhibitor Olaparib (Olaparib, Lynparza).
- a clinical trial of advanced breast cancer patients with BRCA gene mutations and negative HER2 amplification The data shows that the 12-week disease control rate is 80%, the 28-week effective rate is 63%, the 28-week median DoR is 9.2 months, the 28-week median PFS is 8.2 months, and the 28-week disease control rate Is 50%. It is superior to patients who previously received Olaparib monotherapy, with an effective rate of 59.9% and a median PFS of 7.0 months.
- the most common grade 3 adverse reactions associated with olaparib are anemia (12%) and neutropenia (6%); the most common grade 3 adverse reactions associated with durvalumab is pancreatitis (6%).
- the combination of PARP inhibitors and PD-1 antibodies for the treatment of cancer has not only significant therapeutic benefits in the clinic, but still has a greater risk of side effects.
- the side effects are mainly derived from PARP inhibition.
- Agent. Therefore, PARP inhibitors combined with PD-1 antibodies have broad market prospects for the treatment of cancer, and better clinical effects and lower side effects are still the inevitable trend of clinical development.
- the present invention provides a drug combination and application for treating tumors that are different from the prior art.
- the combined use of the components of the drug combination of the present invention can significantly improve the inhibition rate of each single drug on tumor growth, and the mice after administration have no acute adverse reactions, indicating that this combination therapy has a good effect. Safety and effectiveness.
- the present invention provides a pharmaceutical combination comprising a compound represented by formula A, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, and "PD-1 inhibition Agent and/or PD-L1 inhibitor";
- the pharmaceutically acceptable salt of the compound represented by formula A is mefupire hydrochloride.
- the PD-1 inhibitor may be one or more of PD-1 antibody, PD-1 polypeptide, and PD-1 small molecule inhibitor, and further may be Teripril One or more of anti-, sintilizumab, karelizumab, pembrolizumab and nivolizumab, and further may be teriprizumab.
- the PD-L1 inhibitor may be one or more of PD-L1 antibody, PD-L1 polypeptide, and PD-L1 small molecule inhibitor, and further may be ater strain monoclonal antibody (Atezolizumab, trade name Tecentriq), durvalumab (Durvalumab, trade name Imfinzi) and alikuumab (Avelumab, trade name Bavencio) one or more Kind.
- the "PD-1 inhibitor and/or PD-L1 inhibitor” and the compound represented by formula A, its pharmaceutically acceptable salt, and its solvate Or a solvate of a pharmaceutically acceptable salt thereof may be administered simultaneously or separately, and may also be administered separately.
- the separate application can also be sequential application.
- the simultaneous administration may be, "the PD-1 inhibitor and/or PD-L1 inhibitor” and "the compound represented by formula A, its pharmaceutically acceptable salt, and its solvate "Solvate of a substance or a pharmaceutically acceptable salt thereof” includes simultaneous administration in a separate drug combination; or, a separate drug composition including "the PD-1 inhibitor and/or PD-L1 inhibitor” and A single pharmaceutical composition comprising "the compound represented by Formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate" is administered simultaneously.
- Said separate administration may be a separate pharmaceutical composition comprising "the PD-1 inhibitor and/or PD-L1 inhibitor” and a single pharmaceutical composition comprising "the compound represented by formula A, which is pharmaceutically acceptable.
- the individual pharmaceutical compositions of "accepted salts, solvates thereof, or solvates of pharmaceutically acceptable salts thereof" are administered separately at different times.
- the separate administration may be close in time or farther in time.
- the sequential administration may be a separate pharmaceutical composition containing "the PD-1 inhibitor and/or PD-L1 inhibitor" and the "compound of formula A, which is pharmaceutically acceptable.”
- One of the individual pharmaceutical compositions of "accepted salt, solvate thereof, or solvate of a pharmaceutically acceptable salt thereof" is administered first, and the other is administered subsequently.
- the separate administration may be close in time or farther in time.
- the "PD-1 inhibitor and/or PD-L1 inhibitor” and the “compound of formula A, its pharmaceutically acceptable salt, and solvate can be the same or different, and it can be adjusted by those skilled in the art as needed to provide optimal treatment effect.
- the drug combination is mefuropiril hydrochloride and teriprizumab.
- the present invention also provides a pharmaceutical composition X, which comprises:
- the pharmaceutical composition can be made into various suitable dosage forms according to different modes of administration, including dosage forms for administration via the gastrointestinal tract (for example, oral dosage forms (tablets, pills, capsules, powders, granules), gaseous dosage forms (Inhalation)) and parenteral administration dosage forms (e.g. injection dosage forms, ointments, emulsions).
- dosage forms for administration via the gastrointestinal tract for example, oral dosage forms (tablets, pills, capsules, powders, granules), gaseous dosage forms (Inhalation)
- parenteral administration dosage forms e.g. injection dosage forms, ointments, emulsions.
- the pharmaceutical composition X is presented in the form of an injection dosage form or an oral dosage form.
- the oral dosage form can be a tablet form.
- the present invention also provides a pharmaceutical composition Y, which includes the first pharmaceutical composition and the second pharmaceutical composition;
- the first pharmaceutical composition which includes the above-mentioned compound represented by formula A, its pharmaceutically acceptable salt, its solvate or its pharmaceutically acceptable salt solvate, and pharmaceutical excipients ;
- the second pharmaceutical composition includes the above-mentioned "PD-1 inhibitor and/or PD-L1 inhibitor” and pharmaceutical excipients.
- the first pharmaceutical composition is presented in the form of oral dosage form, and further presented in the form of tablet form.
- the second pharmaceutical composition is presented in the form of injection.
- the first pharmaceutical composition is presented in the form of a tablet
- the second pharmaceutical composition is presented in the form of an injection.
- the present invention also provides a medicine kit, which comprises:
- a first container which contains the first pharmaceutical composition as described above;
- the second container contains the second pharmaceutical composition as described above.
- the present invention also provides an application of substance M in the preparation of drugs for the prevention and/or treatment of tumors; wherein, the substance M is the above-mentioned pharmaceutical combination, the above-mentioned pharmaceutical composition X or the above-mentioned pharmaceutical composition Y.
- the tumor may be a solid tumor and/or hematological tumor.
- the solid tumor can be lung cancer, colon cancer, rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, glioma, glial One or more of blastoma, hepatocellular carcinoma, papillary renal cancer, head and neck cancer, leukemia, lymphoma, myeloma, and multiple myeloma.
- the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or the solvate of its pharmaceutically acceptable salt, and, "PD-1 inhibitor And/or PD-L1 inhibitor" administration schedule can be the same or different, which can be adjusted by those skilled in the art as needed to provide the optimal therapeutic effect.
- the "compound of formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate”, and, the "PD-1 inhibitor and The dosage of "PD-L1 inhibitor” can be administered according to the weight of the subject.
- the "compound of formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate", and, "PD- 1 Inhibitor and/or PD-L1 inhibitor” means simultaneous administration or separate administration.
- the administration dose of the "compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate” is 100- 1000mg/time.
- the frequency of administration of the compound represented by Formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate is 0.5-2 times/ day.
- the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate is administered orally.
- the dosage of the "PD-1 inhibitor and/or PD-L1 inhibitor" is 50-500 mg/time.
- the frequency of administration of the "PD-1 inhibitor and/or PD-L1 inhibitor" is once every 7-31 days.
- the "PD-1 inhibitor and/or PD-L1 inhibitor” is administered orally or by injection.
- the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate is administered orally at a dosage of 100-1000mg/kg, the frequency of administration is 0.5-2 times/day;
- the "PD-1 inhibitor and/or PD-L1 inhibitor" is administered by injection, the dosage is 50-500 mg/kg, and the frequency of administration is once every 7-31 days.
- the present invention also provides a compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or a solvate of its pharmaceutically acceptable salt in the preparation of a medicament for the treatment of tumors Application, wherein the “compound represented by formula A, its pharmaceutically acceptable salt, its solvate or its pharmaceutically acceptable salt solvate” is the same as the “PD-1 Inhibitor and/or PD-L1 inhibitor” combined use;
- the "compound represented by formula A, its pharmaceutically acceptable salt, its solvate or its pharmaceutically acceptable salt solvate” and the "PD-1 inhibitor and /Or PD-L1 inhibitor” can be administered simultaneously or separately, or separately.
- the separate application can also be sequential application.
- the compound represented by formula A can be administered orally.
- the dosage of the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate may be 100-1000 mg/kg.
- the frequency of administration of the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate can be 0.5-2 times per day.
- the "PD-1 inhibitor and/or PD-L1 inhibitor” can be administered orally or by injection.
- the dosage of the "PD-1 inhibitor and/or PD-L1 inhibitor” can be 50-500 mg/time.
- the frequency of administration of the "PD-1 inhibitor and/or PD-L1 inhibitor" may be once every 7-31 days.
- the tumor may be a solid tumor and/or hematological tumor.
- the solid tumor can be lung cancer, colon cancer, rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, glioma, glial One or more of blastoma, hepatocellular carcinoma, papillary renal cancer, head and neck cancer, leukemia, lymphoma, myeloma, and multiple myeloma.
- the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate is administered orally at a dosage of 100-1000mg/time, the frequency of administration is 0.5-2 times/day;
- the "PD-1 inhibitor and/or PD-L1 inhibitor" is administered by injection, the dosage is 50-500 mg/time, and the frequency of administration is once every 7-31 days.
- the present invention also provides an application of the above-mentioned "PD-1 inhibitor and/or PD-L1 inhibitor” in the preparation of a medicament for the treatment of tumors, wherein the "PD-1 inhibitor and/or PD-L1 inhibitor” PD-L1 inhibitor” is used in combination with "a compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or its pharmaceutically acceptable salt solvate”;
- the "compound represented by formula A, its pharmaceutically acceptable salt, its solvate or its pharmaceutically acceptable salt solvate” and the "PD-1 inhibitor and /Or PD-L1 inhibitor” can be administered simultaneously or separately, or separately.
- the separate application can also be sequential application.
- the "PD-1 inhibitor and/or PD-L1 inhibitor” can be administered orally or by injection.
- the dosage of the "PD-1 inhibitor and/or PD-L1 inhibitor” can be 50-500 mg/time.
- the frequency of administration of the "PD-1 inhibitor and/or PD-L1 inhibitor" may be once every 7-31 days.
- the compound represented by formula A can be administered orally.
- the dosage of the compound represented by formula A can be 100-1000 mg/time.
- the frequency of administration of the compound represented by formula A can be 0.5-2 times/day.
- the tumor may be a solid tumor and/or hematological tumor.
- the solid tumor can be lung cancer, colon cancer, rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, glioma, glial One or more of blastoma, hepatocellular carcinoma, papillary renal cancer, head and neck cancer, leukemia, lymphoma, myeloma, and multiple myeloma.
- the compound of formula A is orally administered at a dosage of 100-1000 mg/time, and an administration frequency of 0.5-2 times/day;
- the "PD-1 inhibitor and/or PD-L1 inhibitor" is administered by injection, the dosage is 50-500 mg/time, and the frequency of administration is once every 7-31 days.
- the present invention also provides a method for treating or preventing tumors, which comprises administering an effective amount of substance M to a subject, wherein the substance M is the above-mentioned drug combination, the above-mentioned pharmaceutical composition X or the above-mentioned drug Composition Y.
- the tumor may be a solid tumor and/or hematological tumor.
- the solid tumor can be lung cancer, colon cancer, rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, glioma, glial One or more of blastoma, hepatocellular carcinoma, papillary renal cancer, head and neck cancer, leukemia, lymphoma, myeloma, and multiple myeloma.
- the compound represented by formula A, its pharmaceutically acceptable salt, its solvate, or the solvate of its pharmaceutically acceptable salt, and, "PD-1 inhibitor And/or PD-L1 inhibitor" administration schedule (including administration route, administration dosage, administration frequency, etc.) are the same as described above.
- PD-1 antibody refers to an antibody that can bind to PD-1 on the surface of T cells and block the binding of PD-1 to its ligand.
- the full name of PD-1 is programmed cell death protein 1 (programmed cell death protein 1), which is an important immunosuppressive molecule.
- PD-1 polypeptide refers to a polypeptide that can bind to PD-1 on the surface of T cells and block the binding of PD-1 to its ligand.
- PD-1 small molecule inhibitor refers to a small chemical molecule that can bind to PD-1 on the surface of T cells and block the binding of PD-1 to its ligand.
- PD-L1 antibody refers to an antibody that can bind to PD-L1 on the surface of tumor cells and block the binding of PD-L1 to PD-1 on the surface of T cells.
- the full name of PD-L1 is programmed cell death protein 1 ligand 1 (programmed cell death protein 1 ligand 1).
- PD-L1 polypeptide refers to a polypeptide that can bind to PD-L1 on the surface of tumor cells and block the binding of PD-L1 to PD-1 on the surface of T cells.
- PD-L1 small molecule inhibitor refers to a small molecule compound that can bind to PD-L1 on the surface of tumor cells and block the binding of PD-L1 to PD-1 on the surface of T cells.
- Small molecular compound refers to a compound with a molecular weight of less than 1,000.
- pharmaceutically acceptable salt refers to a salt prepared from a compound with a relatively non-toxic, pharmaceutically acceptable acid or base.
- the base addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent.
- Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salt, sodium salt, potassium salt, calcium salt, aluminum salt, magnesium salt, zinc salt, bismuth salt, ammonium salt, and diethanolamine salt.
- the acid addition salt can be obtained by contacting the neutral form of the compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent.
- the pharmaceutically acceptable acids include inorganic acids, and the inorganic acids include but are not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, hydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate Root, phosphorous acid, sulfuric acid, hydrogen sulfate, etc.
- the pharmaceutically acceptable acids include organic acids, including but not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid , Fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, acid citric acid, oleic acid , Tannic acid, pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e.
- solvate refers to a substance formed after a compound crystallizes with a solvent (including but not limited to: water, methanol, ethanol, etc.). Solvates are divided into stoichiometric solvates and non-stoichiometric solvates.
- solvate of a pharmaceutically acceptable salt refers to a compound with a pharmaceutically acceptable (relatively non-toxic, safe, and suitable for patient use) acid or base, solvent (including but not limited to: water, methanol, ethanol) Etc.)
- solvent including but not limited to: water, methanol, ethanol
- Solvates of pharmaceutically acceptable salts include, but are not limited to, hydrochloride monohydrate.
- therapeutically effective amount refers to the amount of a compound administered to a patient that is sufficient to effectively treat the disease.
- the therapeutically effective amount will vary according to the compound, the type of disease, the severity of the disease, the age of the patient, etc., but can be adjusted by those skilled in the art as appropriate.
- the reagents and raw materials used in the present invention are all commercially available.
- the positive progress effect of the present invention is that the pharmaceutical composition of the present invention can inhibit tumor growth by up to 60%, and in the test phase, the subject has no acute adverse reactions.
- Figure 1 shows the percentage change in the body weight of experimental animals after the start of treatment.
- Figure 2 shows the tumor growth curve of experimental animals after the start of treatment.
- Figure 3 shows the individual tumor volume of experimental animals after administration (PG-D24), where "-" represents the median number.
- Figure 4 shows the hCD45FACS detection of the peripheral blood of experimental animals 3 weeks after PBMC inoculation, where "-" represents the median.
- Test drug 1 Tuoyi (Teripril PD-1 monoclonal antibody) injection.
- Test drug 2 Mefuropiril hydrochloride.
- Tuoyi PD-1 monoclonal antibody injection PBS
- Mevoperi hydrochloride physiological saline.
- FBS Fetal Bovine Serum
- Leibovitz's L-15 medium 500ml/bottle Gibco Penicillin mixture 100ml/bottle Solarbio Trypsin-EDTA digestion solution (0.25%) 100ml/bottle Solarbio Matrigel 10ml/bottle Corning PBS (phosphate buffered saline) 500ml/bottle Gibco Normal saline (0.9% sodium chloride injection) 500ml/bottle Shijiazhuang Four Medicines Co., Ltd.
- PE-Cy7 anti-Hu CD45 100Tests Invitrogen
- Mus Musculus Mus Musculus, NCG (NOD-Prkdc em26Cd52 Il2rg em26Cd22 /Nju); gender: female; weight: 18-22g; number: 55; experimental animal provider: Jiangsu Jicui Yaokang Biotechnology Co., Ltd.
- Feeding management The experimental animals are kept in an SPF-level constant temperature and humidity laminar flow clean room, using independent ventilated cages with IVC, one cage for every 5 rats.
- Temperature/Humidity Control in the range of (23 ⁇ 3)°C/40-70%.
- Cage made of polycarbonate. The volume is 370mm ⁇ 155mm ⁇ 135mm. Soft corncobs are autoclaved and cleaned and replaced twice a week. Each cage has a cage label, indicating the number of animals, gender, strain, reception time, group, and start time of the experiment.
- Feed and drinking water SPF rodent feed, sterilized by cobalt 60 irradiation.
- the drinking water is ultra-filtered purified water and is autoclaved. Animals can freely ingest sterile food and drinking water.
- MDA-MB-436 tumor cells (YK-CL-075) were purchased from ATCC. Use Leibovitz's L-15 medium containing inactivated 10% fetal bovine serum, 100U/ml penicillin and 100 ⁇ g/ml streptomycin to cultivate tumor cells in an incubator at 37°C and 5% CO 2 every 3 to 4 After the cells are overgrown, they are divided into bottles for passage, and tumor cells in the logarithmic growth phase are used for tumor inoculation in vivo.
- PBMC human peripheral blood mononuclear cells
- the tumor volume is measured twice a week with a vernier caliper, and the long and short diameters of the tumor are measured.
- T/C value was calculated based on the tumor volume, where T is the average value of the relative tumor volume (RTV) of each test substance treatment group, and C is the average value of the relative tumor volume (RTV) of the control group.
- RTV is the ratio of tumor volume after administration to before administration.
- Tumor growth inhibition rate (TGI, %) (1-T/C) ⁇ 100%.
- the tumor was stripped and weighed, placed neatly and photographed.
- the volume of administration with "*" is 10 ⁇ l/g based on the animal's body weight. If there is a 15-20% weight loss, the drug can be stopped until the body weight returns to a normal level;
- i.p. intraperitoneal injection
- p.o. oral;
- qod ⁇ 13 dosing once every other day for a total of 13 times
- q4d ⁇ 7 dosing once every four days for a total of 7 times.
- mice in each group did not see obvious acute adverse reactions after the administration.
- body weight of mice in each group decreased, as shown in Figure 1.
- the above experiments confirmed that the combined use of Meforpiride hydrochloride + Tuoyi PD-1 monoclonal antibody injection is safe.
- Tuoyi PD-1 monoclonal antibody injection combined with mefupire hydrochloride produced statistically significant anti-tumor effects , Can effectively inhibit tumor growth, and its tumor inhibition rate is significantly higher than that of Tuoyi PD-1 monoclonal antibody injection, and the proportion of hCD45 cells in peripheral blood of mice is correspondingly increased.
Abstract
Description
名称 | 规格 | 生产厂家 |
胎牛血清(FBS) | 500ml/瓶 | Gibco |
Leibovitz's L-15培养基 | 500ml/瓶 | Gibco |
青链霉素混合液 | 100ml/瓶 | Solarbio |
胰蛋白酶-EDTA消化液(0.25%) | 100ml/瓶 | Solarbio |
Matrigel | 10ml/瓶 | Corning |
PBS(磷酸盐缓冲液) | 500ml/瓶 | Gibco |
生理盐水(0.9%氯化钠注射液) | 500ml/瓶 | 石家庄四药有限公司 |
PE-Cy7 anti-Hu CD45 | 100Tests | Invitrogen |
PE-Cy7 mouse IgG1 κ Iso Control | 20Tests | Invitrogen |
名称 | 型号 | 厂家 |
CO 2培养箱 | 3111 | Thermo |
显微镜 | IX53 | Olympus |
电子天平 | EJ-1201C | 北京朗科兴业称重设备有限公司 |
SF2000三按键电子数显卡尺 | 111N-101B | 桂林广陆数字测控有限公司 |
ACEA NovoCyte流式细胞仪 | 3130 | ACEA |
Claims (14)
- 如权利要求1所述的药物组合,其特征在于,所述的如式A所示的化合物药学上可接受的盐为美呋哌瑞盐酸盐;和/或,所述的PD-1抑制剂为PD-1抗体、PD-1多肽和PD-1小分子抑制剂中的一种或多种,进一步可以为特瑞普利单抗、信迪利单抗、卡瑞利珠单抗、帕博利珠单抗和纳武利尤单抗中的一种或多种,进一步还可以为特瑞普利单抗,更进一步可以为拓益;和/或,所述的PD-L1抑制剂为PD-L1抗体、PD-L1多肽和PD-L1小分子抑制剂中的一种或多种,进一步可以为阿特株单抗、度伐单抗和阿利库单抗中的一种或多种;和/或,所述的“PD-1抑制剂和/或PD-L1抑制剂”和所述的“如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物”同时施用或分别施用,进一步为依次施用;和/或,所述的“PD-1抑制剂和/或PD-L1抑制剂”经口服施用或者注射施用;和/或,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物经口服施用。
- 如权利要求1所述的药物组合,其特征在于,所述的药物组合为美呋哌瑞盐酸盐和特瑞普利单抗。
- 一种药物组合物X,其特征在于,所述的药物组合物X包括:如权利要求1~3任一项所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物;如权利要求1~3任一项所述的“PD-1抑制剂和/或PD-L1抑制剂”;和,药用辅料。
- 如权利要求4所述的药物组合物X,其特征在于,所述的药物组合物X以注射剂型形式或口服剂型形式呈现。
- 一种药物组合物Y,其特征在于,所述的药物组合物Y包括第I药物组合物和第II药物组合物;所述的第I药物组合物,其包括如权利要求1~3任一项所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物,和药用辅料;所述的第II药物组合物,其包括如权利要求1~3任一项所述的“PD-1抑制剂和/或PD-L1抑制剂”,和药用辅料。
- 如权利要求6所述的药物组合物Y,其特征在于,所述的第I药物组合物以口服剂型形式呈现,进一步为片剂型形式呈现;和/或,所述的第II药物组合物以注射剂型形式呈现。
- 一种药盒,其包含:第一容器,其包含如权利要求6或7所述的第I药物组合物;和,第二容器,其包含如权利要求6或7所述的第II药物组合物。
- 一种物质M在制备用于预防和/或治疗肿瘤的药物中的应用,其中,所述的物质M为如权利要求1~3任一项所述的药物组合、如权利要求4或5所述的药物组合物X、或、如权利要求6或7所述的药物组合物Y。
- 如权利要求9所述的应用,其特征在于,所述的肿瘤为实体肿瘤和/或血液肿瘤,具体的为肺癌、结肠癌、直肠癌、乳腺癌、前列腺癌、肝癌、胰腺癌、脑癌、肾癌、卵巢癌、胃癌、皮肤癌、骨癌、神经胶质瘤、胶质母细胞瘤、肝细胞癌、乳头状肾癌、头颈癌、白血病、淋巴瘤、骨髓瘤和多发 性骨髓瘤中的一种或多种;和/或,所述的“如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物”和所述的“PD-1抑制剂和/或PD-L1抑制剂”为同时施用或分别施用,进一步为依次施用;和/或,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物的施用剂量为100-1000mg/次;和/或,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物施用频率为0.5-2次/天;和/或,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物经口服施用;和/或,所述的“PD-1抑制剂和/或PD-L1抑制剂”的施用剂量为50-500mg/次;和/或,所述的“PD-1抑制剂和/或PD-L1抑制剂”的施用频率为每7-31天施用一次;和/或,所述的“PD-1抑制剂和/或PD-L1抑制剂”经口服施用或者注射施用。
- 如权利要求10所述的应用,其特征在于,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物经口服施用,施用剂量为100-1000mg/次,施用频率为0.5-2次/天;和,所述的“PD-1抑制剂和/或PD-L1抑制剂”的经注射施用,施用剂量为50-500mg/次,施用频率为每7-31天施用一次。
- 一种如权利要求1~3任一项所述的“如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物”在制备用于治疗肿瘤的药物中的应用,其特征在于,所述的“如式A所示的化合物或其药学上可接受的盐”与如权利要求1~3任一项所述的“PD-1抑制剂和/或PD-L1抑制剂”联用;优选,所述的肿瘤为实体肿瘤和/或血液肿瘤,具体为肺癌、结肠癌、直肠癌、乳腺癌、前列腺癌、肝癌、胰腺癌、脑癌、肾癌、卵巢癌、胃癌、皮肤癌、骨癌、神经胶质瘤、胶质母细胞瘤、肝细胞癌、乳头状肾癌、头颈癌、白血病、淋巴瘤、骨髓瘤和多发性骨髓瘤中的一种或多种。
- 一种如权利要求1~3任一项所述的“PD-1抑制剂和/或PD-L1抑制剂”在制备用于治疗肿瘤的药物中的应用,其特征在于,所述的“PD-1抑制剂和/或PD-L1抑制剂”与如权利要求1~3任一项所述的“如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物”联用;优选,所述的肿瘤为实体肿瘤和/或血液肿瘤,所述的实体肿瘤为肺癌、结肠癌、直肠癌、乳腺癌、前列腺癌、肝癌、胰腺癌、脑癌、肾癌、卵巢癌、胃癌、皮肤癌、骨癌、神经胶质瘤、胶质母细胞瘤、肝细胞癌、乳头状肾癌、头颈癌、白血病、淋巴瘤、骨髓瘤和多发性骨髓瘤中的一种或多种。
- 一种治疗或预防肿瘤的方法,其包括给予受试者使用有效量的物质M,其中,所述的物质M为如权利要求1~3任一项所述的药物组合、如权利要求4或5所述的药物组合物X、或、如权利要求6或7所述的药物组合物Y;优选,所述的如式A所示的化合物、其药学上可接受的盐、其溶剂合物或其药学上可接受的盐的溶剂合物、和、所述的“PD-1抑制剂和/或PD-L1抑制剂”的施用途径、施用剂量和施用频率均同权利要求10或11所述。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20909191.7A EP4085908A4 (en) | 2019-12-31 | 2020-12-31 | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION |
JP2022540813A JP2023509158A (ja) | 2019-12-31 | 2020-12-31 | 腫瘍治療の医薬組み合わせとその使用 |
CA3163564A CA3163564A1 (en) | 2019-12-31 | 2020-12-31 | A drug combination for treating tumors and its application |
US17/790,038 US20230094843A1 (en) | 2019-12-31 | 2020-12-31 | Pharmaceutical combination for treating tumors and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911417368 | 2019-12-31 | ||
CN201911417368.7 | 2019-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136523A1 true WO2021136523A1 (zh) | 2021-07-08 |
Family
ID=76686614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/142257 WO2021136523A1 (zh) | 2019-12-31 | 2020-12-31 | 一种用于治疗肿瘤的药物组合及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230094843A1 (zh) |
EP (1) | EP4085908A4 (zh) |
JP (1) | JP2023509158A (zh) |
CN (1) | CN113116881A (zh) |
CA (1) | CA3163564A1 (zh) |
WO (1) | WO2021136523A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102627620A (zh) * | 2012-04-10 | 2012-08-08 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
CN103242273A (zh) * | 2012-02-09 | 2013-08-14 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
WO2019152989A1 (en) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
CN110382545A (zh) * | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020113246A (ru) * | 2017-10-13 | 2021-11-15 | Мерк Патент Гмбх | Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1 |
-
2020
- 2020-12-31 WO PCT/CN2020/142257 patent/WO2021136523A1/zh unknown
- 2020-12-31 EP EP20909191.7A patent/EP4085908A4/en active Pending
- 2020-12-31 CA CA3163564A patent/CA3163564A1/en active Pending
- 2020-12-31 CN CN202011630763.6A patent/CN113116881A/zh active Pending
- 2020-12-31 JP JP2022540813A patent/JP2023509158A/ja active Pending
- 2020-12-31 US US17/790,038 patent/US20230094843A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103242273A (zh) * | 2012-02-09 | 2013-08-14 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
WO2013117120A1 (zh) | 2012-02-09 | 2013-08-15 | 中国科学院上海药物研究所 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
CN102627620A (zh) * | 2012-04-10 | 2012-08-08 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
CN110382545A (zh) * | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
WO2019152989A1 (en) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
Non-Patent Citations (4)
Title |
---|
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
See also references of EP4085908A4 |
SHIPING JIAO, WEIYA XIA, HIROHITO YAMAGUCHI, YONGKUN WEI, MEI-KUANG CHEN, JUNG-MAO HSU, JENNIFER L. HSU, WEN-HSUAN YU, YI DU, HENG: "PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 23, no. 14, 15 July 2017 (2017-07-15), US, pages 3711 - 3720, XP055567673, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-3215 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023509158A (ja) | 2023-03-07 |
CA3163564A1 (en) | 2021-07-08 |
CN113116881A (zh) | 2021-07-16 |
EP4085908A4 (en) | 2024-01-17 |
US20230094843A1 (en) | 2023-03-30 |
EP4085908A1 (en) | 2022-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105849110B (zh) | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 | |
ES2904880T3 (es) | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 | |
WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
CN104519887B (zh) | 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合 | |
US20230390290A1 (en) | Treatment of her2 positive cancers | |
CN111386128A (zh) | 用于免疫调节的联合疗法 | |
JP2021121611A (ja) | アピリモドを用いる癌の処置方法 | |
CN103533961A (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
CN110191876A (zh) | 用于施用依氟鸟氨酸的制剂 | |
WO2021104454A1 (zh) | Bi853520在癌症治疗中的用途 | |
UA121392C2 (uk) | Комбінація, яка містить глюкокортикоїд і edo-s101 | |
TW201138764A (en) | Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents | |
WO2023035223A1 (zh) | 药物组合物及其用途 | |
JP2018509459A (ja) | がん治療薬との併用療法におけるnk−92細胞 | |
TW202108165A (zh) | 治療癌症之方法 | |
KR20210019422A (ko) | 암 치료 방법 | |
TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
CN101429201A (zh) | 柠檬酸小檗胺盐及制备方法和应用 | |
WO2021136523A1 (zh) | 一种用于治疗肿瘤的药物组合及其应用 | |
WO2023104151A1 (zh) | 治疗肿瘤的药物组合及用途 | |
TW201100081A (en) | Treatment of pancreatic cancer | |
WO2019042226A1 (zh) | 用于肿瘤治疗或预防的药物组合物、方法及其用途 | |
CA3208122A1 (en) | Methods of treatment with s1p receptor modulators | |
TW201306833A (zh) | 包含康布列塔司他汀(combretastatins)族衍生物及西妥昔單抗(cetuximab)之組合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20909191 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022540813 Country of ref document: JP Kind code of ref document: A Ref document number: 3163564 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020909191 Country of ref document: EP Effective date: 20220801 |